It is better to anticipate any potential issues that might result in a 483 Observation by creating and implementing processes to avoid this scenario. Trying to repair the issues brought forward as the result of a 483 Observation is not only expensive, but very disruptive to the company, often negatively impacting employee morale.
Once the inspection has been completed, the company will receive a draft of the Establishment Inspection Report (EIR), as well as drafts of any 483 Observations. The inspector will submit these documents to the company before leaving the facility. Upon receipt of 483 Observations, the company has 15 days to respond.
If you receive a 483 Observation, the situation needs to be handled with care. First and foremost, you should review the documents with the inspector before he/she leaves the facility. You do not have much time to address these challenges, so having a full understanding of the documents and what needs to be done to correct the issues is critical.
A 483 Observation does not need to be addressed in writing; however, it is considered good practice to do so. It is also good practice to address your response to the district director with a courtesy copy to the lead investigator.
A Warning Letter is an official deficiency letter from the FDA, which is sent as a consequence of an unsuccessful inspection by the investigators of the agency. Before a Warning Letter is issued, the FDA requests the company to comment on the deficiencies listed in the 483 Observations found during the inspection. If the FDA judges this response to be unacceptable, a Warning Letter will be issued.
Typically, Warning Letters are sent to ensure overnight delivery and receipt of delivery (e.g., return receipt requested, FedEx). As with an FDA 483 Observation, the company has 15 days maximum to respond in writing. However, if the cause of the Warning Letter is severe, the FDA may shorten the deadline.
Like 483 Observations, Warning Letters can be very costly and can significantly delay time to market and consume capital in the process.
Once the FDA has determined that a company has significant violations to their regulatory policies and issued a Warning Letter, in order to remedy the issues raised, the following steps should be taken:
The response letter should contain an opening statement that discusses how the company is serious about resolving the issue, what the date of the inspection was, and what the address of the site was.
The letter should also include a context for the situation, a restatement of the observation and the reference number, and a discussion of any related operations that were compliant.
Other content in the response letter depends on whether corrective actions have been taken yet and how long the corrections would take. For instance, if the corrections would take several months, the letter should include what measures personnel are going to take to be compliant in the interim.